000164098 001__ 164098
000164098 005__ 20240229123205.0
000164098 0247_ $$2doi$$a10.3390/cancers12103012
000164098 0247_ $$2pmid$$apmid:33081402
000164098 037__ $$aDKFZ-2020-02244
000164098 041__ $$aeng
000164098 082__ $$a610
000164098 1001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b0$$eFirst author$$udkfz
000164098 245__ $$aCommonly Applied Selection Criteria for Lung Cancer Screening May Have Strongly Varying Diagnostic Performance in Different Countries.
000164098 260__ $$aBasel$$bMDPI$$c2020
000164098 3367_ $$2DRIVER$$aarticle
000164098 3367_ $$2DataCite$$aOutput Types/Journal article
000164098 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1603713827_16618
000164098 3367_ $$2BibTeX$$aARTICLE
000164098 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164098 3367_ $$00$$2EndNote$$aJournal Article
000164098 500__ $$a#EA:C070#LA:C070#
000164098 520__ $$aLung cancer (LC) screening often focuses heavy smokers as a target for screening group. Heavy smoking can thus be regarded as an LC pre-screening test with sensitivities and specificities being different in various populations due to the differences in smoking histories. We derive here expected sensitivities and specificities of various criteria to preselect individuals for LC screening in 27 European countries with diverse smoking prevalences. Sensitivities of various heavy-smoking-based pre-screening criteria were estimated by combining sex-specific proportions of people meeting these criteria in the target population for screening with associations of heavy smoking with LC risk. Expected specificities were approximated by the proportion of individuals not meeting the heavy smoking definition. Estimated sensitivities and specificities varied widely across countries, with sensitivities being generally higher among men (range: 33-80%) than among women (range: 9-79%), and specificities being generally lower among men (range: 48-90%) than among women (range: 70-99%). Major variation in sensitivities and specificities was also seen across different pre-selection criteria for LC screening within individual countries. Our results may inform the design of LC screening programs in European countries and serve as benchmarks for novel alternative or complementary tests for selecting people at high risk for CT-based LC screening.
000164098 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000164098 588__ $$aDataset connected to CrossRef, PubMed,
000164098 7001_ $$0P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aKrilaviciute, Agne$$b1$$eLast author$$udkfz
000164098 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers12103012$$gVol. 12, no. 10, p. 3012 -$$n10$$p3012$$tCancers$$v12$$x2072-6694$$y2020
000164098 909CO $$ooai:inrepo02.dkfz.de:164098$$pVDB
000164098 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000164098 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000164098 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000164098 9141_ $$y2020
000164098 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2019-12-21
000164098 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2019-12-21
000164098 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2019-12-21
000164098 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000164098 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000164098 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000164098 980__ $$ajournal
000164098 980__ $$aVDB
000164098 980__ $$aI:(DE-He78)C070-20160331
000164098 980__ $$aI:(DE-He78)C120-20160331
000164098 980__ $$aI:(DE-He78)HD01-20160331
000164098 980__ $$aUNRESTRICTED